Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer

Rhea-AI Summary

Pyramid Biosciences has appointed Dr. Nushmia Khokhar as the new Chief Medical Officer to lead the company's clinical pipeline advancements. Dr. Khokhar, previously with Umoja Biopharma and Autolus Therapeutics, brings extensive experience in oncology clinical development. The CEO, Brian Lestini, expressed confidence in her leadership during this growth phase. Dr. Khokhar's background includes significant roles at Johnson & Johnson, where she directed successful clinical trials for cancer therapies. Pyramid Biosciences focuses on creating precision therapies for serious diseases.

Positive

• Appointment of Dr. Nushmia Khokhar as Chief Medical Officer may enhance clinical pipeline development.
• Dr. Khokhar has a strong track record in oncology clinical development, previously leading successful trials at major companies.

Negative

• None.

• Dr. Khokhar will oversee the advancement and expansion of the Company’s clinical pipeline
• Dr. Khokhar joins Pyramid Biosciences from Umoja Biopharma where she served as Chief Medical Officer

WALTHAM, Mass.--(BUSINESS WIRE)-- Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer, where she will oversee the advancement and expansion of the Company’s clinical pipeline.

“Dr. Khokhar has a proven track record of successfully bringing novel oncology compounds through clinical development to global approval,” said CEO of Pyramid Biosciences, Brian Lestini, MD, PhD. “We are looking forward to Dr. Khokhar’s leadership of our clinical programs during this important growth stage of our company.”

Prior to joining Pyramid Biosciences, Dr. Khokhar served as Chief Medical Officer at Umoja Biopharma, a multi-platform, immuno-oncology company based in Seattle, WA. In this capacity, Dr. Khokhar oversaw Umoja’s clinical development, operations, and regulatory functions. Prior to joining Umoja, Dr. Khokhar was the Senior Vice President & Head of Clinical Development at Autolus Therapeutics, where she played a critical role in advancing the company’s autologous CAR T-cell products and clinical programs. Prior to that, Dr. Khokhar held numerous roles at Janssen Oncology, a subsidiary of Johnson & Johnson (NYSE: JNJ) where she led several successful clinical trials, directed the Phase 3 registration trial of trabectedin (YONDELIS^®) in soft tissue sarcomas, and served as the Global Clinical Leader for the breakthrough therapy daratumumab (DARZALEX^®) for hematologic cancers.

“I look forward to working with the outstanding team at Pyramid Biosciences, progressing the Company's promising therapies through clinical development and building a robust pipeline,” said Dr. Khokhar.

“We are extremely pleased to have Nushmia join our senior leadership team as we continue to grow our clinical programs and develop new medicines for underserved patients,” said Jordan Leef, Pyramid Biosciences’ Co-Founder & COO.

Dr. Khokhar is a graduate of Aga Khan University and completed her post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center, where she focused on pharmacology and molecular therapeutics. Following her post-doctoral fellowship, Dr. Khokhar completed a residency in internal medicine at Washington Hospital Center and a fellowship in Hematology/Oncology at the Northwestern University Hospital. Dr. Khokhar is board certified in medical oncology.

About Pyramid Biosciences:

Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company dedicated to developing a portfolio of precision therapies targeting a targeting a range of serious diseases. Pyramid is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: www.pyramidbio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005067/en/

Pyramid Biosciences Media Inquiries:

McDougall Communications on behalf of Pyramid Biosciences

Elizabeth Harness, +1-585-435-7379

elizabeth@mcdougallpr.com

Pyramid Biosciences Investor Inquiries:

Jordan Leef, Pyramid Biosciences, COO, CBO, and Co-Founder

+1-781-530-4461, info@pyramidbio.com

Source: Pyramid Biosciences, Inc.

FAQ

Who is the new Chief Medical Officer of Pyramid Biosciences?

Dr. Nushmia Khokhar has been appointed as the new Chief Medical Officer of Pyramid Biosciences.

What experience does Dr. Nushmia Khokhar bring to Pyramid Biosciences?

Dr. Khokhar has extensive experience in oncology clinical development, having served as Chief Medical Officer at Umoja Biopharma and held key roles at Autolus Therapeutics and Johnson & Johnson.

What is the focus of Pyramid Biosciences?

Pyramid Biosciences is focused on developing precision therapies for cancer and other serious diseases.

When was Pyramid Biosciences founded?

Pyramid Biosciences was founded in 2015.

What key roles did Dr. Khokhar hold before joining Pyramid Biosciences?

Before joining, Dr. Khokhar was Chief Medical Officer at Umoja Biopharma and Senior Vice President at Autolus Therapeutics.